Triprolidin
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Actidil, Myidyl, Triprolidine HCL, Triprolidine Hydrochloride |
| Drugs.com | Monografija |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 4 - 6 h |
| Identifikatori | |
| CAS broj | 486-12-4  |
| ATC kod | R06AX07 (WHO) |
| PubChem | CID 5282443 |
| IUPHAR/BPS | 1228 |
| DrugBank | DB00427 |
| ChemSpider | 4445597 |
| ChEMBL | CHEMBL855 |
| Hemijski podaci | |
| Formula | C19H22N2 |
| Molarna masa | 278,391 |
| |
| |
| Fizički podaci | |
| Tačka topljenja | 60 °C (140 °F) |
Triprolidin je organsko jedinjenje, koje sadrži 19 atoma ugljenika i ima molekulsku masu od 278,391 Da.[1][2][3][4][5][6]
Osobine
[уреди | уреди извор]| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 2 |
| Broj donora vodonika | 0 |
| Broj rotacionih veza | 4 |
| Particioni koeficijent[7] (ALogP) | 4,1 |
| Rastvorljivost[8] (logS, log(mol/L)) | -5,2 |
| Polarna površina[9] (PSA, Å2) | 16,1 |
Reference
[уреди | уреди извор]- ^ Mann, K. V.; Crowe, J. P.; Tietze, K. J. (1989). „Nonsedating histamine H1-receptor antagonists”. Clinical Pharmacy. 8 (5): 331—344. PMID 2568212.
- ^ Simons, F. E. (1994). „H1-receptor antagonists. Comparative tolerability and safety”. Drug Safety. 10 (5): 350—380. PMID 7913608. doi:10.2165/00002018-199410050-00002.
- ^ Paton, D. M.; Webster, D. R. (1985). „Clinical pharmacokinetics of H1-receptor antagonists (The antihistamines)”. Clinical Pharmacokinetics. 10 (6): 477—497. PMID 2866055. doi:10.2165/00003088-198510060-00002.
- ^ Telekes, A.; Holland, R. L.; Withington, D. A.; Peck, A. W. (1987). „Effects of triprolidine and dipipanone in the cold induced pain test, and the central nervous system of healthy volunteers”. Br J Clin Pharmacol. 24 (1): 43—50. PMC 1386278
. PMID 3620284. doi:10.1111/j.1365-2125.1987.tb03134.x.
- ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
- ^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
- ^ Tetko, I. V.; Tanchuk, V. Y.; Kasheva, T. N.; Villa, A. E. (2001). „Estimation of aqueous solubility of chemical compounds using E-state indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl, P.; Rohde, B.; Selzer, P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
[уреди | уреди извор]- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
[уреди | уреди извор]
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
